US OptionsDetailed Quotes

IMMP241220P7500

Watchlist
  • 0.00
  • 0.000.00%
15min DelayTrading Nov 25 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    我要向钱看
    我要向钱看
    Nov 21 20:43
    LOOKING REAL GOOD...
    Immutep Limited Passes All AGM Resolutions
    Immutep Ltd (AU:IMM) has released an update.
    Immutep Limited announced that all resolutions proposed at their 2024 Annual General Meeting were successfully passed, showcasing strong shareholder support. The company, a leader in LAG-3 immunotherapy for cancer and autoimmune diseases, continues to focus on advancing its innovative treatment options. This positive outcome is likely to strengthen investor confidence and potentially i...
    我要向钱看
    我要向钱看
    Nov 21 19:59
    UPDATES
    $Immutep (IMMP.US)$ Immutep (ASX:IMM) will focus on developing its cancer treatment lead candidate eftilagmod alpha in fiscal 2025, Chair Russel Howard said at the annual general meeting, according to a Friday filing with the Australian bourse.
    The lead candidate will be evaluated in the phase 3 TACTI-004 trial to investigate its use in patients with first-line non-small cell lung cancer. The trial is set to start later in the year or early next year, the filing said.
    The biotechnology f...
    我要向钱看
    我要向钱看
    Nov 18 00:30
    ON THE WATCH LIST
    $Immutep (IMMP.US)$
    Add AU:IMM to your watchlist
    Immutep Ltd has witnessed a notable increase in its voting power, with Regal Funds Management Pty Limited and its associates now holding 11.79% of the company’s shares, up from 10.59%. This shift, involving various financial entities like UBS and Merrill Lynch, highlights a growing interest in Immutep’s market potential. Investors keen on stock dynamics should keep an eye on these developments for future implications.
    我要向钱看
    我要向钱看
    Nov 15 06:53
    UPDATES
    $Immutep (IMMP.US)$ Baird analyst Joel Beatty maintains $Immutep (IMMP.US)$ with a buy rating, and adjusts the target price from $6 to $7.
    我要向钱看
    我要向钱看
    Nov 14 07:36
    UPDATES
    $Immutep (IMMP.US)$ 
    Immutep (IMMP) announces the presentation of new data from EFTISARC-NEO, a Phase II investigator-initiated trial of eftilagimod alpha in combination with radiotherapy plus KEYTRUDA for patients with soft tissue sarcoma, STS, at the Connective Tissue Oncology Society, CTOS, 2024 Annual Meeting. Based on preliminary analysis among 21 patients available for primary endpoint assessment, the triple combination therapy demonstrates significant efficacy in the neoadjuvant se...
Read more